Clinical trial
The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control
NCT00279201 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2005
- Completion date
- November 30, 2009
- Enrollment
- 2,091 (actual)
- Sites
- 199
Conditions
As the registry lists them; a condition with its own page is linked.